SEC Form 4 · accession 0001114220-17-000018
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A Holmes
Officer — Chief Financial Officer
Period of report
Jul 28, 2017
Accepted (ET)
Jul 31, 2017 · 4:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 28, 2017 | S | 1,236 | $6.96 | D | 143,727 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 1,236 shares of common stock was made in order to satisfy Mr. Holmes' income tax withholding obligation upon the vesting of 3,750 shares of restricted stock on July 27, 2017. Mr. Holmes had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F2Includes 95,100 shares of restricted stock.